Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 5
2004 5
2005 8
2006 4
2007 5
2008 7
2009 6
2010 7
2011 9
2012 7
2013 12
2014 12
2015 18
2016 13
2017 9
2018 12
2019 16
2020 21
2021 30
2022 16
2023 15
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Results by year

Filters applied: . Clear all
Page 1
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Cutsem EV, Winkler RE, Makris L, Ilson DH, Tabernero J. Shitara K, et al. Among authors: fujitani k. Lancet Oncol. 2018 Nov;19(11):1437-1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21. Lancet Oncol. 2018. PMID: 30355453 Clinical Trial.
Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
Kawazoe A, Ando T, Hosaka H, Fujita J, Koeda K, Nishikawa K, Amagai K, Fujitani K, Ogata K, Watanabe K, Yamamoto Y, Shitara K. Kawazoe A, et al. Among authors: fujitani k. Lancet Gastroenterol Hepatol. 2021 Mar;6(3):209-217. doi: 10.1016/S2468-1253(20)30396-4. Epub 2021 Jan 26. Lancet Gastroenterol Hepatol. 2021. PMID: 33508242 Clinical Trial.
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Hironaka S, et al. Among authors: fujitani k. J Clin Oncol. 2013 Dec 10;31(35):4438-44. doi: 10.1200/JCO.2012.48.5805. Epub 2013 Nov 4. J Clin Oncol. 2013. PMID: 24190112 Clinical Trial.
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T; REGATTA study investigators. Fujitani K, et al. Lancet Oncol. 2016 Mar;17(3):309-318. doi: 10.1016/S1470-2045(15)00553-7. Epub 2016 Jan 26. Lancet Oncol. 2016. PMID: 26822397 Clinical Trial.
Chemoradiotherapy versus triplet chemotherapy as initial therapy for T4b esophageal cancer: survival results from a multicenter randomized Phase 2 trial.
Yamasaki M, Miyata H, Yamashita K, Hamakawa T, Tanaka K, Sugimura K, Makino T, Takeno A, Shiraishi O, Motoori M, Kimura Y, Hirao M, Fujitani K, Yasuda T, Yano M, Eguchi H, Doki Y. Yamasaki M, et al. Among authors: fujitani k. Br J Cancer. 2023 Jul;129(1):54-60. doi: 10.1038/s41416-023-02286-y. Epub 2023 May 4. Br J Cancer. 2023. PMID: 37142731 Clinical Trial.
[FOLFOX].
Mishima H, Ikenaga M, Tsujinaka T, Yasui M, Kashiwazaki M, Miyazaki M, Hirao M, Fujitani K, Nakamori S. Mishima H, et al. Among authors: fujitani k. Gan To Kagaku Ryoho. 2006 Jul;33(7):911-4. Gan To Kagaku Ryoho. 2006. PMID: 16835479 Japanese.
Comparison of synbiotics combined with enteral nutrition and prophylactic antibiotics as supportive care in patients with esophageal cancer undergoing neoadjuvant chemotherapy: A multicenter randomized study.
Motoori M, Sugimura K, Tanaka K, Shiraishi O, Kimura Y, Miyata H, Yamasaki M, Makino T, Miyazaki Y, Iwama M, Yamashita K, Niikura M, Sugimoto T, Asahara T, Fujitani K, Yasuda T, Doki Y, Yano M. Motoori M, et al. Among authors: fujitani k. Clin Nutr. 2022 May;41(5):1112-1121. doi: 10.1016/j.clnu.2022.03.023. Epub 2022 Apr 1. Clin Nutr. 2022. PMID: 35413573 Clinical Trial.
Three-Course Neoadjuvant Chemotherapy Associated with Unfavorable Survival of Non-responders to the First Two Courses for Locally Advanced Esophageal Cancer.
Kubo Y, Makino T, Yamasaki M, Tanaka K, Yamashita K, Shiraishi O, Sugimura K, Miyata H, Motoori M, Fujitani K, Takeno A, Hirao M, Kimura Y, Satoh T, Yano M, Eguchi H, Yasuda T, Doki Y. Kubo Y, et al. Among authors: fujitani k. Ann Surg Oncol. 2023 Sep;30(9):5899-5907. doi: 10.1245/s10434-023-13548-7. Epub 2023 Jun 14. Ann Surg Oncol. 2023. PMID: 37316744 Clinical Trial.
Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials.
Kimura Y, Kawakami H, Tamura S, Fujitani K, Matsuyama J, Imamura H, Iijima S, Sakai D, Kurokawa Y, Shimokawa T, Tsujinaka T, Furukawa H, Satoh T. Kimura Y, et al. Among authors: fujitani k. Gastric Cancer. 2023 Sep;26(5):788-797. doi: 10.1007/s10120-023-01408-y. Epub 2023 Jun 19. Gastric Cancer. 2023. PMID: 37335367
212 results